{
  "symbol": "ABSI",
  "company": "Absci Corporation",
  "generated_at": "2026-06-24T07:36:44.231Z",
  "event_count": 4,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-06T15:30:03.645Z",
      "stage": "cooldown",
      "outcome": "skip",
      "reason": "recent analyst:skip 17.1h ago < cooldown 168h, no material change",
      "trigger": "watchlist rotation · core · frontier-2030s",
      "source": "watchlist"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-05T22:26:06.751Z",
      "skip": true,
      "reason": "Anti-signals for low liquidity, dilution, and high cash burn (~$100M/yr on $125M cash) create unacceptable structural risk; combined with a binary H2 2026 catalyst priced into extreme IV and a >130% YTD run, there is no favorable entry or income structure that justifies the risk.",
      "score": 13,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 2,
        "catalyst": 8,
        "mispricing": 0,
        "quality": 0,
        "technical": 3
      },
      "debug_path": "drafts/2026-06-05-ABSI.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-05T22:25:22.926Z",
      "summary": "Absci is an AI-native clinical-stage biopharma whose lead program ABS-201 targets prolactin receptor (PRLR) for androgenetic alopecia and endometriosis. The June 5 8-K was routine (annual meeting), but the real near-term catalyst is Phase 1/2a HEADLINE trial interim proof-of-concept data expected H2 2026 — all four SAD cohorts have been dosed with favorable safety, MAD dosing initiated. Chief Innovation Officer Andreas Busch made a substantial open-market purchase of 100,000 shares at $2.29 in March 2026 (~$229K), and options flow is overwhelmingly bullish call-skew. However, the stock has already run ~134% YTD and sits near its 52-week high, trading above both MAs with no obvious entry point for a new long position without pulling back.",
      "verdict": "range_bound_or_income",
      "confidence": 5,
      "tool_calls": 18,
      "walltime_min": 28,
      "debug_path": "dossiers/2026-06-05-ABSI.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-09T04:32:59.572Z",
      "summary": "ABSI is a clinical-stage AI-native biopharmaceutical company whose shares have doubled year-to-date on the back of positive early Phase 1 data for lead asset ABS-201 (anti-PRLR antibody in androgenetic alopecia and endometriosis). The Q1 2026 earnings report (filed May 7) confirmed all four planned SAD cohorts dosed with favorable safety, MAD cohort initiated, and a new pipeline program (ABS-202) disclosed. Smart money shows one significant insider open-market purchase by Chief Innovation Officer Andreas Busch (100K shares at $2.29 in March 2026), plus director Menelas Pangalos buying on market. No CEO or CFO purchases are present; the CFO was net-selling for tax withholding during a vest. The stock is near its 52-week high ($5.90 vs. $6.235 high) with an RSI of 79 — deeply overbought short-term despite strong medium-term momentum and a bullish analyst consensus (7 analysts, median target ~$8). Valuation metrics are meaningless for a pre-revenue biotech; the narrative hinges entirely on Phase 1/2a ABS-201 proof-of-concept data expected in H2 2026. Options flow is heavily call-biased with a 0.19 put/call ratio and net $55K directional bias, but no whale blocks.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 22,
      "walltime_min": 50,
      "debug_path": "dossiers/2026-05-09-ABSI.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "ABSI",
    "call": "BUY",
    "confidence": 5,
    "score": 7,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_up": "+2 (81.1%)",
      "rsi_neutral": "0 (58.8)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (6d ago)",
      "from_high": "0 (-11.8%)"
    },
    "summary": "BUY (score +7) · 12-1 mom 81.1% · RSI 58.8 · above_both · -11.8% from high",
    "last_close": 7.41,
    "one_month_ago_close": 5.09,
    "twelve_month_ago_close": 2.81,
    "twelve_one_momentum_pct": 81.14,
    "rsi_14": 58.8,
    "ma_stack": "above_both",
    "from_period_high_pct": -11.79,
    "period_high": 8.4,
    "price_targets": {
      "bear": 3.76,
      "fair": 7.5,
      "bull": 15,
      "bear_return_pct": -49.3,
      "fair_return_pct": 1.2,
      "bull_return_pct": 102.4,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 4.1,
        "target_mean": 9.61,
        "target_high": 15,
        "analyst_count": 10
      }
    },
    "generated_at": "2026-06-24T07:36:44.226Z"
  }
}